NIH Clinical Center Search the Studies: Study Number, Study Title

Protocol Details

Hematologic Malignancy Biology Study

This study is currently recruiting participants.

Summary | Eligibility | Citations | Contacts

Summary

Number

04-C-0102

Sponsoring Institute

National Cancer Institute (NCI)

Recruitment Detail

Type: Enrolling by Invitation
Gender: Male & Female
Min Age: 1 Years
Max Age: 75 Years

Referral Letter Required

Yes

Population Exclusion(s)

Neonates

Keywords

Acute Lymphoblastic Leukemia;
Acute Lymphocytic Leukemia;
Pediatric Blood Disorders;
Hodgkins and non-Hodgkins lymphoma;
MDS;
Natural History

Recruitment Keyword(s)

None

Condition(s)

Acute Lymphoblastic Leukemia;
Myelodysplastic Syndrome (MDS);
Non-Hodgkins Lymphoma;
Acute Myelogenous Leukemia;
Hodgkins Lymphoma

Investigational Drug(s)

None

Investigational Device(s)

None

Intervention(s)

None

Supporting Site

National Cancer Institute

This study will collect tumor samples from people with cancers of the blood, bone marrow, or lymph glands for laboratory study of the biology of these conditions. Such studies contribute to a better understanding of cancer biology and to the development of new treatments. Planned studies include:

- Examination of individual cancer cells and to search for differences compared to other types of cancer and normal cells

- Examination of the chromosomes and genes in cancer cells and to search for differences compared to other types of cancer and normal cells

- Development of sensitive methods to detect small amounts of cancer that remain after treatment

- Search for new cancer proteins that might serve as targets for treatment

- Investigation of methods to develop cancer vaccines.

Patients from >= 1 to 75 years of age with acute lymphocytic leukemia, acute myelogenous leukemia, myelodysplastic syndrome, chronic myelogenous leukemia, juvenile myelomonocytic leukemia, non-Hodgkin's lymphoma, Hodgkin's disease, and other hematologic malignancies may be eligible for this study.

Blood or bone marrow samples will be collected when sampling is required for the patient's medical care. Cells from some individuals will be grown in test tubes, establishing cell lines or in animals, establishing xenograft models. (A xenograft is transplantation of cells of one species to another species.)

--Back to Top--

Eligibility

INCLUSION CRITERIA

Confirmed pathological diagnosis of any hematologic malignancy or pre-malignant blood disorder, including but not restricted to the following:

Acute Lymphocytic Leukemia (ALL)

Acute Myelogenous Leukemia (AML)

Myelodysplastic Syndrome (MDS)

Chronic Myelogenous Leukemia (CML)

Juvenile Myelomonocytic Leukemia (JMML, J-CML)

Non-Hodgkin's Lymphoma (NHL)

Hodgkin's Disease

Tumor tissue that has been previously collected and is available for study or that can be collected with minimal additional risk to the subject during sampling required for routine patient care.

Patient age: >= 1 to 75 years.

Prior therapy: no restrictions

Subject, parent/guardian, legally authorized representative (LAR), or durable power of attorney must be able to give informed consent and sign the informed consent document.

EXCLUSION CRITERIA

None


--Back to Top--

Citations:

Not Provided

--Back to Top--

Contacts:

Principal Investigator

Referral Contact

For more information:

Nirali N. Shah, M.D.
National Cancer Institute (NCI)
NIHBC 10 - CRC BG RM 1-5750
10 CENTER DR
BETHESDA MD 20892
(240) 760-6970
shahnn@mail.nih.gov

NCI Pediatric Leukemia, Lymphoma Transpl
National Cancer Institute (NCI)

(240) 760-6970
ncilltct@mail.nih.gov

NCI Referral Office
National Institute of Health Clinical Center (CC), 9000 Rockville Pike, Bethesda, Maryland 20892, United States: NCI Clinical Trials Referral Office
1-888-NCI-1937

Clinical Trials Number:

NCT00923442

--Back to Top--